Meet Oncologist Michael Hurwitz, MD, PhD

Why It Matters

Cellular immunotherapies are redefining urogenital cancer care, offering curative options for some patients while turning others into manageable chronic conditions, thereby influencing treatment standards and biotech investment.

Key Takeaways

• Hurwitz treats prostate, kidney, bladder, and testicular cancers.
• He leads a cellular immunotherapy program for solid tumors.
• Therapies use autologous or allogeneic immune cells, modified ex vivo.
• Several cell-based treatments have transitioned from trials to standard practice.
• Uncurable cancers are treated as chronic conditions, similar to heart disease.

Summary

The video introduces Dr. Michael Hurwitz, MD, PhD, an oncologist who focuses on urogenital malignancies—including prostate, kidney, bladder, and testicular cancers—and heads a solid‑tumor cellular immunotherapy program.

Hurwitz explains that his team harvests patients’ own immune cells or donor cells, engineers them outside the body, and reinfuses them to target tumors. While many of these approaches remain experimental, several—such as CAR‑T and engineered NK cells—have already entered standard practice, expanding the therapeutic arsenal beyond surgery, radiation, and chemotherapy.

He emphasizes a patient‑centered strategy: “We meet the patient where they are,” and acknowledges that not all cancers are curable today, so treatment often shifts to a chronic‑disease model akin to managing heart disease or diabetes.

The shift toward personalized cellular therapies signals a broader industry trend toward durable, targeted cancer solutions, reshaping clinical pathways, reimbursement models, and biotech investment priorities.

Original Description

For more information on Dr. Hurwitz or #YaleMedicine, visit: https://www.yalemedicine.org/specialists/michael-hurwitz.

Michael Hurwitz, MD, PhD, is a medical oncologist who cares for people with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers. He uses immune cell-based therapies to treat a wide range of solid tumors. “As a clinician, my goal is to provide the best clinical care to my patients,” Dr. Hurwitz says. “To do that, I think it is paramount to address patients’ goals and desires.” As an associate professor of medicine (medical oncology) at Yale School of Medicine, Dr. Hurwitz focuses on expanding clinical trials for immune cell-based treatments. He collaborates with scientists to develop new approaches for improving outcomes in kidney and other solid tumor cancers. He is also the co-director of the Cell Therapy Clinical Research Program at Yale Cancer Center. Dr. Hurwitz received his medical degree from Cornell University Medical College and earned a doctoral degree from Rockefeller University. He completed a residency in internal medicine at The NewYork-Presbyterian Hospital/Weill Cornell Medical Center, followed by a fellowship in adult oncology at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital.